◀ Back to IL6

ARSA — IL6

Text-mined interactions from Literome

Minuz et al., Br J Pharmacol 2001 : We tested the effects of NCX4016 and ASA on the release of the thromboxane ( TX ) A ( 2 ) metabolite TXB ( 2 ), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) , expression and activity of tissue factor ( TF ) in stimulated, adherent human monocytes
Brzozowski et al., J Pharmacol Exp Ther 2004 (Stomach Diseases) : The area of ASA induced gastric lesions, gastric blood flow ( GBF ), expression of mRNA and protein of leptin and plasma leptin, gastrin, interleukin-1beta , and tumor necrosis factor-alpha levels were examined
Berger et al., Exp Neurol 2008 (Brain Ischemia...) : To assess the effects of acetylsalicylic acid (ASA) on glutamate and interleukin-6 (IL-6) release in the striatum of rats suffering from cerebral ischemia, we used the microdialysis technique with probes implanted 2 h prior to stroke onset
Ogston et al., Int J Obes Relat Metab Disord 2008 (Obesity) : The effect of acetylsalicylic acid (ASA) , an inhibitor of COX, on IL-6 was assessed in human subjects and mice ... In obese humans, low-dose ASA ( 150 mg day ( -1 ) for 10 days ) inhibited systemic IL-6 and reduced IL-6 release from SC WAT ex vivo ( 0.2 mM ) ... Similarly, in mice, ASA ( 0.2 and 2.0 mg kg ( -1 ) ) suppressed SC WAT 6-keto-PGF ( 1alpha ) ( a stable metabolite of prostacyclin ) and IL-6 release ... Both ASA ( 5 mM ) and NS-398 ( COX-2 selective inhibitor < or=1 microM ), but not SC-560 ( COX-1 selective inhibitor < or=1 microM ), attenuated IL-6 release from murine WAT in vitro and abolished its depot differences